NLS Pharmaceutics

We design affordable, safe and effective drugs to safeguard and empower the brain throughout all stages of life. Our aim is to improve quality of life and longevity. We are creating new approaches to treat mental and behavioral disorders, and to enhance cognitive function in healthy people.

  • About
    • Our DNA
    • Mission & Values
    • Team
  • Science
    • R&D Strategy
    • R&D Focus
    • Pipeline
    • Mazindol
  • Partnering
    • Industry Partnerships
    • Academic Collaborations
  • News
    • Press Releases
    • Press Room
    • Awards
  • Investors
    • Stock Information
    • Presentations
    • SEC Filings
    • Corporate Governance
    • Financial Information
    • Corporate Code of Ethics
  • Contact

Financial Information

  • Home
  • Investors
  • Financial Information
Financial Information
Condensed Balance Sheets as of June 30, 2020 and December 31, 2019 (unaudited)
Condensed Statements of Operations and Comprehensive Loss for the Six Months Ended June 30, 2020 and 2019 (unaudited)
Condensed Statement of Changes in Shareholders’ Deficit for the Six Months Ended June 30, 2020 and 2019 (unaudited)
Condensed Statements of Cash Flows for the Six Months Ended June 30, 2020 and 2019 (unaudited)
 Notes to Unaudited Condensed Financial Statements 
© 2019 NLS Pharmaceutics. All rights reserved.

This site uses cookies: Find out more.